title: Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.
abstract: The demonstration in humans and mice that nucleic acid-sensing TLRs and type I IFNs are essential disease mediators is a milestone in delineating the mechanisms of lupus pathogenesis. In this study, we show that Ifnb gene deletion does not modify disease progression in NZB mice, thereby strongly implicating IFN-α subtypes as the principal pathogenic effectors. We further document that long-term treatment of male BXSB mice with an anti-IFN-α/β receptor Ab of mouse origin reduced serologic, cellular, and histologic disease manifestations and extended survival, suggesting that disease acceleration by the Tlr7 gene duplication in this model is mediated by type I IFN signaling. The efficacy of this treatment in BXSB mice was clearly evident when applied early in the disease process, but only partial reductions in some disease characteristics were observed when treatment was initiated at later stages. A transient therapeutic effect was also noted in the MRL-Fas(lpr) model, although overall mortality was unaffected. The combined findings suggest that IFN-α/β receptor blockade, particularly when started at early disease stages, may be a useful treatment approach for human systemic lupus erythematosus and other autoimmune syndromes.
authors.affiliation: Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA. rbaccala@scripps.edu
authors.forename: Roberto
authors.initials: R
authors.lastname: Baccala
authors.forename: Rosana
authors.initials: R
authors.lastname: Gonzalez-Quintial
authors.forename: Robert D
authors.initials: RD
authors.lastname: Schreiber
authors.forename: Brian R
authors.initials: BR
authors.lastname: Lawson
authors.forename: Dwight H
authors.initials: DH
authors.lastname: Kono
authors.forename: Argyrios N
authors.initials: AN
authors.lastname: Theofilopoulos
mesh_terms: D000818:Animals; D000974:Antibodies, Antinuclear / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D001323:Autoantibodies / Q000008:administration & dosage* / Q000096:biosynthesis / Q000627:therapeutic use; D002478:Cells, Cultured; D020022:Genetic Predisposition to Disease / Q000209:etiology; D006801:Humans; D008181:Lupus Nephritis / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D019463:Mice, Inbred MRL lpr; D008814:Mice, Inbred NZB; D018345:Mice, Knockout; D011507:Proteinuria / Q000235:genetics / Q000276:immunology / Q000628:therapy; D053633:Receptor, Interferon alpha-beta / Q000276:immunology*
chemical_list: D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D001323:Autoantibodies; C508032:Ifnar1 protein, mouse; D053633:Receptor, Interferon alpha-beta